Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLFS BioLife Solutions	$24.34 -3.9%	$22.16	$19.10 ▼ $29.55	$1.21B	1.76	539,985 shs	1.30 million shs
CATX Perspective Therapeutics	$3.61 -7.4%	$3.76	$1.60 ▼ $16.55	$289.49M	1.17	949,022 shs	647,645 shs
ESTA Establishment Labs	$38.32 +1.0%	$40.78	$26.56 ▼ $50.85	$1.10B	0.83	478,149 shs	373,098 shs
MDXG MiMedx Group	$7.11 -0.6%	$6.57	$5.47 ▼ $10.14	$1.06B	1.79	873,588 shs	310,344 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLFS BioLife Solutions	-3.87%	+7.32%	+15.68%	+3.18%	-6.02%
CATX Perspective Therapeutics	-7.44%	-1.90%	-11.52%	+37.26%	-72.94%
ESTA Establishment Labs	+0.97%	+10.11%	-12.23%	+5.97%	-7.68%
MDXG MiMedx Group	-0.56%	+1.28%	+5.96%	+0.85%	+15.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLFS BioLife Solutions	3.2088 of 5 stars	3.6	3.0	3.1	2.5	0.6
CATX Perspective Therapeutics	1.6964 of 5 stars	3.6	1.0	2.5	0.8	0.0
ESTA Establishment Labs	2.077 of 5 stars	3.4	0.0	2.5	2.5	0.6
MDXG MiMedx Group	3.2125 of 5 stars	3.5	4.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLFS BioLife Solutions	3.13	Buy	$31.29	28.54% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	247.80% Upside
ESTA Establishment Labs	2.80	Moderate Buy	$55.80	45.62% Upside
MDXG MiMedx Group	3.00	Buy	$12.00	68.78% Upside

Current Analyst Ratings Breakdown

Latest CATX, BLFS, MDXG, and ESTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BLFS BioLife Solutions	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	BLFS BioLife Solutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $32.00
7/31/2025	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$11.00 ➝ $12.00
7/22/2025	BLFS BioLife Solutions	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00
7/16/2025	ESTA Establishment Labs	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$58.00 ➝ $70.00
7/15/2025	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/9/2025	ESTA Establishment Labs	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$38.00 ➝ $47.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/13/2025	ESTA Establishment Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$48.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLFS BioLife Solutions	$82.25M	14.17	$0.12 per share	206.67	$7.25 per share	3.36
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
ESTA Establishment Labs	$166.02M	6.69	N/A	N/A	$0.79 per share	48.51
MDXG MiMedx Group	$348.88M	3.02	$0.33 per share	21.58	$1.46 per share	4.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLFS BioLife Solutions	-$20.18M	-$0.12	N/A	N/A	N/A	-5.39%	0.16%	0.14%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	N/A
ESTA Establishment Labs	-$84.60M	-$3.05	N/A	N/A	N/A	-49.89%	-224.34%	-25.53%	N/A
MDXG MiMedx Group	$42.42M	$0.21	33.86	22.22	N/A	8.84%	23.03%	17.09%	10/29/2025 (Estimated)

Latest CATX, BLFS, MDXG, and ESTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BLFS BioLife Solutions	-$0.02	-$0.33	-$0.31	-$0.33	$23.71 million	$25.42 million
8/7/2025	Q2 2025	ESTA Establishment Labs	-$0.54	-$0.57	-$0.03	-$0.57	$50.80 million	$51.30 million
7/30/2025	Q2 2025	MDXG MiMedx Group	$0.06	$0.10	+$0.04	$0.06	$90.79 million	$98.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
ESTA Establishment Labs	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLFS BioLife Solutions	0.03	4.43	3.45
CATX Perspective Therapeutics	N/A	9.60	9.60
ESTA Establishment Labs	9.71	2.84	1.67
MDXG MiMedx Group	0.08	4.39	3.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLFS BioLife Solutions	93.24%
CATX Perspective Therapeutics	54.66%
ESTA Establishment Labs	72.91%
MDXG MiMedx Group	79.15%

Insider Ownership

Company	Insider Ownership
BLFS BioLife Solutions	2.20%
CATX Perspective Therapeutics	3.72%
ESTA Establishment Labs	11.09%
MDXG MiMedx Group	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLFS BioLife Solutions	440	47.90 million	46.85 million	Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
ESTA Establishment Labs	1,018	28.97 million	25.76 million	Optionable
MDXG MiMedx Group	870	147.96 million	145.44 million	Optionable

CATX, BLFS, MDXG, and ESTA Headlines

Recent News About These Companies

Koss Olinger Consulting LLC Raises Stake in MiMedx Group, Inc (NASDAQ:MDXG)

August 11, 2025 | marketbeat.com

Federated Hermes Inc. Decreases Stake in MiMedx Group, Inc (NASDAQ:MDXG)

August 11, 2025 | marketbeat.com

There May Be Reason For Hope In MiMedx Group's (NASDAQ:MDXG) Disappointing Earnings

August 7, 2025 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and MiMedx Group (MDXG)

August 5, 2025 | theglobeandmail.com

MiMedx Group Inc. Reports Record Earnings and Growth

August 4, 2025 | theglobeandmail.com

MiMedx Group (MDXG) Receives a Buy from Northland Securities

August 4, 2025 | theglobeandmail.com

Phocas Financial Corp. Buys 202,265 Shares of MiMedx Group, Inc (NASDAQ:MDXG)

August 4, 2025 | marketbeat.com

MiMedx Group (NASDAQ:MDXG) Stock Rating Upgraded by Wall Street Zen

August 3, 2025 | marketbeat.com

Results: MiMedx Group, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

August 2, 2025 | finance.yahoo.com

Cantor Fitzgerald Forecasts Higher Earnings for MiMedx Group

August 2, 2025 | marketbeat.com

Northland Capmk Raises Earnings Estimates for MiMedx Group

August 2, 2025 | marketbeat.com

MiMedx Group (NASDAQ:MDXG) Shares Gap Up Following Analyst Upgrade

August 1, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Strong Price Appreciation for MiMedx Group (NASDAQ:MDXG) Stock

August 1, 2025 | marketbeat.com

MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript

July 30, 2025 | seekingalpha.com

MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates

July 30, 2025 | zacks.com

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

July 30, 2025 | globenewswire.com

MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

July 30, 2025 | globenewswire.com

SA analyst upgrades/downgrades: OXY, AMZN, MDXG, CHTR

July 30, 2025 | msn.com

MiMedx Group, Inc (NASDAQ:MDXG) Shares Sold by Royce & Associates LP

July 28, 2025 | marketbeat.com

MiMedx: Reimbursement Hurdles Mask A Compelling Valuation Opportunity (Rating Upgrade)

July 25, 2025 | seekingalpha.com

MiMedx Group (MDXG) to Release Earnings on Wednesday

July 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CATX, BLFS, MDXG, and ESTA Company Descriptions

BioLife Solutions NASDAQ:BLFS

$24.34 -0.98 (-3.87%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$24.59 +0.25 (+1.03%)

As of 08/15/2025 06:54 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Perspective Therapeutics NYSE:CATX

$3.61 -0.29 (-7.44%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.05 (+1.41%)

As of 08/15/2025 07:00 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Establishment Labs NASDAQ:ESTA

$38.32 +0.37 (+0.97%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$38.52 +0.20 (+0.52%)

As of 08/15/2025 07:48 PM Eastern

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

MiMedx Group NASDAQ:MDXG

$7.11 -0.04 (-0.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.12 +0.00 (+0.07%)

As of 08/15/2025 04:20 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time